Consistent with previously literature, by analyzing clinical databases, and confirmation in different breast cancer cell lines, we report downregulated CEMM protein CAV1 in breast cancer and its association with poor clinical prognosis (Figures 6A, 6B, and S5A–S5D).88, 89, 90 We firstly linked CAV1 downregulation to Doxo resistance in breast cancer treatment.91 The gene discussed is CAV1; the disease is breast carcinoma.